# Detection of PitNET Tissue During TSS Using Bevacizumab-800CW

> **NCT04212793** · PHASE1 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 20 (actual)

## Conditions studied

- Pituitary Tumor
- Pituitary Adenoma
- Pituitary Macroadenoma

## Interventions

- **DRUG:** Bevacizumab-IRDye800CW
- **DEVICE:** Molecular Fluorescence Endoscopy platform

## Key facts

- **NCT ID:** NCT04212793
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-28
- **Primary completion:** 2022-10-24
- **Final completion:** 2022-10-24
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04212793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04212793, "Detection of PitNET Tissue During TSS Using Bevacizumab-800CW". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04212793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*